Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03460704 · ClinicalTrials.gov registry record · Phase 3
Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.
A Phase 3 study, sponsored by Zambon SpA.
- Terminated
- Registry status
- Phase 3
- Development phase
- 287
- Enrollment target
NCT03460704 is a Phase 3 study that was terminated before completion, run by Zambon SpA. The registered enrollment target is 287 participants.
The verdict
NCT03460704, a Phase 3 study, was terminated before completion, sponsored by Zambon SpA.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 287 participants
- Enrollment target
Study Summary
The primary objective of the trial was to investigate the effect of the use of inhaled colistimethate sodium (CMS), administered twice a day (b.i.d.) via a specific nebulizer for 12 months, compared to placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on the annualised frequency of pulmonary exacerbations.
Interventions
- OTHER Placebo
- DRUG CMS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2018-01-29 |
| Est. Completion | 2022-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03460704
The ClinicalTrials.gov registry entry for NCT03460704 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zambon SpA, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03460704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03460704 about?
NCT03460704 is a clinical study titled "Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.". The primary objective of the trial was to investigate the effect of the use of inhaled colistimethate sodium (CMS), administered twice a day (b.i.d.) via a specific nebulizer for 12 months, compared to placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. ae...
What is the current status of trial NCT03460704?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 287 participants. The study started on 2018-01-29. Estimated completion is 2022-03-15.
What interventions are being tested in trial NCT03460704?
The interventions under investigation include: Placebo (OTHER), CMS (DRUG).
Who is sponsoring clinical trial NCT03460704?
This trial is sponsored by Zambon SpA, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.